Mirum(US:MIRM) ZACKS·2025-05-07 22:30分组1 - Mirum Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the Zacks Consensus Estimate of a loss of $0.39, and improved from a loss of $0.54 per share a year ago, representing an earnings surprise of 23.08% [1] - The company posted revenues of $111.59 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 13.32%, and compared to year-ago revenues of $69.22 million [2] - Mirum Pharmaceuticals has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has lost about 0.9% since the beginning of the year, while the S&P 500 has declined by 4.7% [3] - The current consensus EPS estimate for the coming quarter is -$0.35 on revenues of $102.78 million, and for the current fiscal year, it is -$1.23 on revenues of $427.82 million [7] - The Medical - Biomedical and Genetics industry is currently in the top 35% of Zacks industries, indicating a favorable outlook for stocks within this sector [8]